2. Anti-infection Autophagy
  3. Bacterial Autophagy
  4. Amoxapine

Amoxapine (CL-67772) is a norepinephrine reuptake blocker and a 5-HT2/5-HT3 antagonist. Amoxapine can be used for the research of depression. Amoxapine has antibacterial activity. Amoxapine can enhance the killing effect of macrophages on mycobacterium by inducing autophagy, while protecting the cells from death.

For research use only. We do not sell to patients.

Amoxapine Chemical Structure

Amoxapine Chemical Structure

CAS No. : 14028-44-5

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 66 In-stock
Solution
10 mM * 1 mL in DMSO USD 66 In-stock
Solid
250 mg USD 60 In-stock
500 mg USD 78 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Amoxapine:

Amoxapine Related Antibodies

Top Publications Citing Use of Products

    Amoxapine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Nov 10;13(1):6796.  [Abstract]

    10 µM Amoxapine (Amo), Desloratadine (Desl) and Maprotiline (Map) are incubated with HEK293T cells for 24 h and significantly inhibits PERK phosphorylation and expression of ATF4 and CHOP .

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Amoxapine (CL-67772) is a norepinephrine reuptake blocker and a 5-HT2/5-HT3 antagonist. Amoxapine can be used for the research of depression. Amoxapine has antibacterial activity. Amoxapine can enhance the killing effect of macrophages on mycobacterium by inducing autophagy, while protecting the cells from death[1][2][3].

    IC50 & Target

    5-HT Receptor and Serotonin Transporter[3]
    Cellular Effect
    Cell Line Type Value Description References
    RAW264.7 CC50
    107.1 μM
    Compound: Loxapine
    Cytotoxicity against mouse RAW264.7 cells assessed as reduction in number of cells by DAPI staining based high-content image analysis
    Cytotoxicity against mouse RAW264.7 cells assessed as reduction in number of cells by DAPI staining based high-content image analysis
    		[PMID: 36439974]
    In Vitro

    Amoxapine (10 μM; 3-48 h) reduces the cytotoxicity induced by mycobacterium bovis (BCG) and inhibits the survival of BCG in macrophages. The minimum inhibitory concentration (MIC90) for BCG is 53 μM[1].
    Amoxapine (10 μM; 24 h) induces autophagy in mycobacteria-infected macrophages in a mTOR-dependent manner[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Amoxapine Related Antibodies

    Cell Viability Assay[1]

    Cell Line: BCG treated RAW 264.7 cells
    Concentration: 10 μM
    Incubation Time: 3 h
    Result: Reduced the percentage of dead cells.

    Western Blot Analysis[1]

    Cell Line: BCG treated RAW 264.7 cells
    Concentration: 10 μM
    Incubation Time: 24 h
    Result: Significantly enhanced levels of LC3B-II protein and reduced levels of p62.
    Significantly reduced the ratio of phosphorylation at Ser 2448 of mTOR to total mTOR.
    In Vivo

    Amoxapine (3-5 mg/kg; Oral administration; 2 weeks) enhances host defense against M. tuberculosis (Mtb) in mouse models[1].
    Amoxapine (10 mg/kg; Intraperitoneal injection; 28 days) can affect the electrophysiology of rat atrial[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Mtb strain H37Rv treated BALB/c and C57BL/6 mice[1]
    Dosage: 3 and 5 mg/kg
    Administration: Oral administration (p.o.); 2 weeks
    Result: Significantly reduced bacterial burdens in the lungs.
    Enhanced host defense against Mtb in vivo.
    Animal Model: Sprague-Dawley rats (200-300g)[2]
    Dosage: 10 mg/kg
    Administration: Intraperitoneal injection (i.p.); 28 days
    Result: Reduced atrial rate, contractile force and df/dtmax prolonged the sinus node recovery time and decreased atrial excitability.
    Decreased amplitude and Vmax of the upstroke, prolonged the duration of the action potential (APD) and effective refractory period (ERP) and reduced the resting membrane potential.
    Inhibited the slow action potentials and contractions induced by isoprenaline in Kdepolarized atria.
    Molecular Weight

    313.79

    Formula

    C17H16ClN3O
    CAS No.
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    ClC1=CC=C(OC2=CC=CC=C2N=C3N4CCNCC4)C3=C1
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : 8.33 mg/mL (26.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.1869 mL 15.9343 mL 31.8687 mL
    5 mM 0.6374 mL 3.1869 mL 6.3737 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 1.56 mg/mL (4.97 mM); Clear solution

      This protocol yields a clear solution of ≥ 1.56 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (15.6 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 1.56 mg/mL (4.97 mM); Clear solution

      This protocol yields a clear solution of ≥ 1.56 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (15.6 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.93%

    SDS (393 KB)

    COA (256 KB) HNMR (238 KB) LCMS (105 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.1869 mL 15.9343 mL 31.8687 mL 79.6716 mL
    5 mM 0.6374 mL 3.1869 mL 6.3737 mL 15.9343 mL
    10 mM 0.3187 mL 1.5934 mL 3.1869 mL 7.9672 mL
    15 mM 0.2125 mL 1.0623 mL 2.1246 mL 5.3114 mL
    20 mM 0.1593 mL 0.7967 mL 1.5934 mL 3.9836 mL
    25 mM 0.1275 mL 0.6374 mL 1.2747 mL 3.1869 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Amoxapine Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Amoxapine14028-44-5CL-67772CL67772CL 67772BacterialAutophagyDepressionAntibacterial activityRAW 264.7 cellsInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Amoxapine
    Cat. No.:
    HY-B0991
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.